Form 4 for RLMD RELMADA THERAPEUTICS, INC.
Accepted 2026-09-11 07:30:03 ET · period of report 2026-09-09 · accession 0001213900-26-098970 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2026-09-11 07:30 | 2026-09-09+ | RLMD | Shenouda Maged | CFO | P - Purchase | $4.22 | +200.0K | 1.00M | +25% | +$844.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-09-09 | P | A | 120,200 | $4.20 | 920,200 | D | — | — | (F1) The number of securities reported represents an aggregate number of shares purchased in multiple open market transactions over a range of purchase prices. The price reported represents the weighted average price. The Reporting Person undertakes to provide to the staff of the SEC, the Issuer, or a stockholder of the Issuer, upon request, the number of shares purchased by the Reporting Person at each separate price within the range. (F2) Purchase prices range from $4.16 to $4.20 per share, inclusive. |
| 2 | Common | Common Stock | 2026-09-10 | P | A | 79,800 | $4.25 | 1,000,000 | D | — | — |